Evofem Biosciences, Inc. (NASDAQ:EVFM) Short Interest Update

Evofem Biosciences, Inc. (NASDAQ:EVFM) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 12,070,000 shares, a growth of 30.8% from the March 31st total of 9,230,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Shares of Evofem Biosciences stock opened at $1.35 on Wednesday. The firm’s 50-day simple moving average is $1.87 and its 200-day simple moving average is $2.53. Evofem Biosciences has a twelve month low of $1.33 and a twelve month high of $6.87. The firm has a market cap of $112.22 million, a P/E ratio of -0.69 and a beta of 0.07.

Evofem Biosciences (NASDAQ:EVFM) last announced its earnings results on Wednesday, March 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.14). The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.70 million. Sell-side analysts predict that Evofem Biosciences will post -1.52 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Evofem Biosciences in the fourth quarter worth about $26,000. HighTower Advisors LLC bought a new stake in shares of Evofem Biosciences during the fourth quarter worth approximately $27,000. Citigroup Inc. raised its stake in shares of Evofem Biosciences by 218.8% during the fourth quarter. Citigroup Inc. now owns 14,609 shares of the biotechnology company’s stock worth $35,000 after buying an additional 10,026 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of Evofem Biosciences during the fourth quarter worth approximately $41,000. Finally, Tudor Investment Corp Et Al bought a new stake in shares of Evofem Biosciences during the fourth quarter worth approximately $45,000. 44.84% of the stock is owned by institutional investors.

Separately, HC Wainwright dropped their target price on shares of Evofem Biosciences from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $9.07.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.

Featured Story: Stock Market – What is a circuit breaker?

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit